Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MMH-522 in Healthy Volunteers
NCT07754279Phase 1Completed
- Sponsor
- Materia Medica Holding
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of MMH-522 in cough (4 arms), sponsored by Materia Medica Holding. Primary endpoint: Number of adverse events (AEs) with toxicity grade 3 or higher at 7 days. Started Feb 2026; status: completed.
02
Drugs
MMH-522
03
Conditions
cough
Beyond the preview
Go deeper on NCT07754279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754279.